

Santiago Osorio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5623625/publications.pdf>

Version: 2024-02-01

8
papers

97
citations

1684188

5
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

179
citing authors

#	ARTICLE	IF	CITATIONS
1	A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 734-738.	0.9	4
2	Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e985-e999.	0.4	13
3	Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1041-1048.	2.4	7
4	Error Detection and Cost Savings With an Image-Based Workflow Management System Connected to a Computerized Prescription Order Entry Program for Antineoplastic Compounding. <i>Journal of Patient Safety</i> , 2019, Publish Ahead of Print, e1589-e1594.	1.7	3
5	Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 484-486.	0.9	5
6	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018, 8, 91.	6.2	38
7	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. <i>Annals of Hematology</i> , 2018, 97, 2089-2098.	1.8	18
8	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. <i>PLoS ONE</i> , 2017, 12, e0181366.	2.5	8